EUVIMEDEUVIMED entdecken
Crossref

Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy

Yi-Ze Qi, Zhi-Yuan Wang, Xiang-Dong Li

World Journal of Cardiology · 05.11.2026

DOI: 10.4330/wjc.127591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Cardiology, online erschienen am 05.11.2026. Verfasst von Yi-Ze Qi und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Qi, Y., Wang, Z., & Li, X. (2026). Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy. World Journal of Cardiology. https://doi.org/10.4330/wjc.127591

Vancouver

Qi Y, Wang Z, Li X. Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy. World Journal of Cardiology. 2026. doi:10.4330/wjc.127591

BibTeX
@article{Qi2026,
  author = {Qi, Yi-Ze and Wang, Zhi-Yuan and Li, Xiang-Dong},
  title = {Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy},
  journal = {World Journal of Cardiology},
  year = {2026},
  doi = {10.4330/wjc.127591}
}
Kostenlos starten →